Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study

New biologic agents targeting interleukin (IL)23/T‐helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected by moderate‐to‐severe psoriasis over a 28‐week treatment...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Dermatologic therapy 2022-06, Vol.35 (6), p.e15488-n/a
Hauptverfasser: Caldarola, Giacomo, Galluzzo, Marco, Bernardini, Nicoletta, Calabrese, Laura, Grimaldi, Marta, Moretta, Gaia, Pagnanelli, Gianluca, Shumak, Ruslana Gaeta, Talamonti, Marina, Tofani, Lorenzo, Pallotta, Sabatino, Peris, Ketty, Potenza, Concetta, De Simone, Clara, Campione, Elena
Format: Artikel
Sprache:eng
Schlagworte:
efficacy
interleukin‐23
Original
psoriasis
real‐life
safety
tildrakizumab
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:New biologic agents targeting interleukin (IL)23/T‐helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected by moderate‐to‐severe psoriasis over a 28‐week treatment period. A multicentric retrospective study was conducted in patients who initiated tildrakizumab between February 2020 and March 2021. Psoriasis Area and Severity Index—PASI was measured at baseline and after 4, 16 and 28 weeks. The percentage change in PASI value from baseline to the considered time‐points, proportion of patients with absolute PASI
ISSN:1396-0296
1529-8019
DOI:10.1111/dth.15488